78 related articles for article (PubMed ID: 22440084)
1. Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.
Imai M; Takahashi N
Bioorg Med Chem; 2012 Apr; 20(8):2520-6. PubMed ID: 22440084
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
Takahashi N; Takeda K; Imai M
Bioorg Med Chem; 2013 Oct; 21(19):6015-21. PubMed ID: 23953690
[TBL] [Abstract][Full Text] [Related]
3. Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
Ohba T; Yamauch T; Higashiyama K; Takahashi N
Bioorg Med Chem; 2007 Jan; 15(2):847-53. PubMed ID: 17092729
[TBL] [Abstract][Full Text] [Related]
4. Anticancer and superoxide scavenging activities of p-alkylaminophenols having various length alkyl chains.
Takahashi N; Honda T; Ohba T
Bioorg Med Chem; 2006 Jan; 14(2):409-17. PubMed ID: 16203149
[TBL] [Abstract][Full Text] [Related]
5. Antioxidant and anticancer activities of novel p-alkylaminophenols and p-acylaminophenols (aminophenol analogues).
Takahashi N; Ohba T; Yamauchi T; Higashiyama K
Bioorg Med Chem; 2006 Sep; 14(17):6089-96. PubMed ID: 16725328
[TBL] [Abstract][Full Text] [Related]
6. Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.
Takahashi N; Koyama S; Hasegawa S; Yamasaki M; Imai M
Bioorg Med Chem Lett; 2017 Oct; 27(20):4664-4672. PubMed ID: 28927789
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumor agent, p-DDAP potently suppresses proliferation through apoptosis in human neuroblastoma NB-39-nu cells.
Takahashi N; Egawa R; Imai M; Takahashi K; Ohba T; Imaizumi M
Cancer Lett; 2010 Nov; 297(2):252-8. PubMed ID: 20580487
[TBL] [Abstract][Full Text] [Related]
8. p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action.
Takahashi N; Watanabe Y; Maitani Y; Yamauchi T; Higashiyama K; Ohba T
Int J Cancer; 2008 Feb; 122(3):689-98. PubMed ID: 17955489
[TBL] [Abstract][Full Text] [Related]
9. Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells.
Chan-On W; Huyen NT; Songtawee N; Suwanjang W; Prachayasittikul S; Prachayasittikul V
Drug Des Devel Ther; 2015; 9():2033-47. PubMed ID: 25897210
[TBL] [Abstract][Full Text] [Related]
10. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
11. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.
Nakajima T; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Abe T; Kato J; Sakon K; Naniwa Y; Tanabe H; Niitsu Y
J Pharmacol Exp Ther; 2003 Sep; 306(3):861-9. PubMed ID: 12805482
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of di-phenyl-tin(IV)-salicyliden-ortho-aminophenols: analysis of in vitro antitumor/antioxidant activities and molecular structures.
Beltrán HI; Damian-Zea C; Hernández-Ortega S; Nieto-Camacho A; Ramírez-Apan MT
J Inorg Biochem; 2007 Jul; 101(7):1070-85. PubMed ID: 17555822
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells.
Banti I; Nencetti S; Orlandini E; Lapucci A; Breschi MC; Fogli S
J Pharm Pharmacol; 2009 Aug; 61(8):1057-66. PubMed ID: 19703350
[TBL] [Abstract][Full Text] [Related]
14. Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway.
Shin-Kang S; Ramsauer VP; Lightner J; Chakraborty K; Stone W; Campbell S; Reddy SA; Krishnan K
Free Radic Biol Med; 2011 Sep; 51(6):1164-74. PubMed ID: 21723941
[TBL] [Abstract][Full Text] [Related]
15. Monocillin II inhibits human breast cancer growth partially by inhibiting MAPK pathways and CDK2 Thr160 phosphorylation.
Wei H; Xu L; Yu M; Zhang L; Wang H; Wei X; Ruan Y
Chembiochem; 2012 Feb; 13(3):465-75. PubMed ID: 22253097
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing the cytotoxicity of α-methylene-γ-hydroxy esters against pancreatic cancer.
Ramachandran PV; Helppi MA; Lehmkuhler AL; Marchi JM; Schmidt CM; Yip-Schneider MT
Bioorg Med Chem Lett; 2015 Oct; 25(19):4270-3. PubMed ID: 26264501
[TBL] [Abstract][Full Text] [Related]
17. The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model.
Takiguchi S; Nishino Y; Inoue K; Ikeda M; Kataoka Y; Matsusue K; Nishiyama K; Iguchi H
Oncol Rep; 2012 Jul; 28(1):111-6. PubMed ID: 22484715
[TBL] [Abstract][Full Text] [Related]
18. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives.
Lan P; Wang J; Zhang DM; Shu C; Cao HH; Sun PH; Wu XM; Ye WC; Chen WM
Eur J Med Chem; 2011 Jun; 46(6):2490-502. PubMed ID: 21496972
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic anticancer activity of a novel geranylgeranylated coumarin derivative.
Devji T; Reddy C; Woo C; Awale S; Kadota S; Carrico-Moniz D
Bioorg Med Chem Lett; 2011 Oct; 21(19):5770-3. PubMed ID: 21880488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
